471 related articles for article (PubMed ID: 34193311)
1. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.
Semitala FC; Musinguzi A; Ssemata J; Welishe F; Nabunje J; Kadota JL; Berger CA; Katamba A; Kiwanuka N; Kamya MR; Dowdy D; Cattamanchi A; Katahoire AR
Implement Sci Commun; 2021 Jun; 2(1):71. PubMed ID: 34193311
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
Kadota JL; Musinguzi A; Nabunje J; Welishe F; Ssemata JL; Bishop O; Berger CA; Patel D; Sammann A; Katahoire A; Nahid P; Belknap R; Phillips PPJ; Namusobya J; Kamya M; Handley MA; Kiwanuka N; Katamba A; Dowdy D; Semitala FC; Cattamanchi A
Implement Sci; 2020 Aug; 15(1):65. PubMed ID: 32787925
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
[TBL] [Abstract][Full Text] [Related]
4. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
5. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
Mapingure MP; Zech JM; Hirsch-Moverman Y; Msukwa M; Howard AA; Makoni T; Gwanzura C; Apollo T; Sandy C; Musuka GN; Rabkin M
J Int AIDS Soc; 2023 Jun; 26(6):e26105. PubMed ID: 37339341
[TBL] [Abstract][Full Text] [Related]
6. Contextualizing and optimizing novel strategies to improve the latent TB continuum of care: Insights from people living with HIV and health care providers in Brazil.
Salles I; Travassos P; Spener-Gomes R; Loch AP; Saraceni V; Lauria L; Cavalcante S; Garcia de Oliveira J; Brito de Souza A; Guimarães Costa A; Sakabe S; Schiavon Nogueira R; Chaisson LH; Cohn S; Jamal LF; Valdez Ramalho Madruga J; Cordeiro-Santos M; Castro B; Portella Ferreira D; Hoffmann CJ; Golub JE; Durovni B; Kerrigan D
PLOS Glob Public Health; 2023; 3(1):e0001251. PubMed ID: 36962892
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
8. Developing strategies to address barriers for tuberculosis case finding and retention in care among refugees in slums in Kampala, Uganda: a qualitative study using the COM-B model.
Buregyeya E; Atusingwize E; Sekandi JN; Mugambe R; Nuwematsiko R; Atuyambe L
BMC Infect Dis; 2022 Mar; 22(1):301. PubMed ID: 35346094
[TBL] [Abstract][Full Text] [Related]
9. Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach.
Ayakaka I; Ackerman S; Ggita JM; Kajubi P; Dowdy D; Haberer JE; Fair E; Hopewell P; Handley MA; Cattamanchi A; Katamba A; Davis JL
Implement Sci; 2017 Mar; 12(1):33. PubMed ID: 28274245
[TBL] [Abstract][Full Text] [Related]
10. Integration of COVID-19 and TB screening in Kampala, Uganda: healthcare provider perspectives.
Semitala FC; Katwesigye R; Kalibbala D; Mbuliro M; Lalitha R; Owachi D; Atine E; Nassazi J; Turyahabwe S; Sekadde M
Implement Sci Commun; 2023 Jan; 4(1):8. PubMed ID: 36650596
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
13. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
Jacobson KB; Niccolai L; Mtungwa N; Moll AP; Shenoi SV
AIDS Care; 2017 Jul; 29(7):936-942. PubMed ID: 28147705
[TBL] [Abstract][Full Text] [Related]
14. Integration of COVID-19 and TB screening in Kampala, Uganda - Healthcare provider perspectives.
Semitala FC; Katwesigye R; Kalibbala D; Mbuliro M; Opio R; Owachi D; Atine E; Nassazi J; Turyahabwe S; Sekadde M
Res Sq; 2022 Jun; ():. PubMed ID: 35702151
[No Abstract] [Full Text] [Related]
15. Stakeholders' Perceptions of Benefits of and Barriers to Using Video-Observed Treatment for Monitoring Patients With Tuberculosis in Uganda: Exploratory Qualitative Study.
Sekandi JN; Kasiita V; Onuoha NA; Zalwango S; Nakkonde D; Kaawa-Mafigiri D; Turinawe J; Kakaire R; Davis-Olwell P; Atuyambe L; Buregyeya E
JMIR Mhealth Uhealth; 2021 Oct; 9(10):e27131. PubMed ID: 34704961
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis.
Roscoe C; Lockhart C; de Klerk M; Baughman A; Agolory S; Gawanab M; Menzies H; Jonas A; Salomo N; Taffa N; Lowrance D; Robsky K; Tollefson D; Pevzner E; Hamunime N; Mavhunga F; Mungunda H
BMC Public Health; 2020 Dec; 20(1):1838. PubMed ID: 33261569
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis preventive treatment uptake among people living with HIV during COVID-19 period in Addis Ababa, Ethiopia: a retrospective data review.
Gebreegziabher SB; Ashuro AA; Kumssa TH; Teferi MY; Alemayue EA; Datiko DG; Yimer SA; Shagre MB
BMC Infect Dis; 2024 May; 24(1):499. PubMed ID: 38760665
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017-2019.
Ssendikwanawa E; Juniour Nsubuga E; Lee S; Frances Zalwango J; Joan Bayowa R; Judith Ssemasaazi A; Ronald Muganga K; Adolphus C; Akunzirwe R; Nante Wangi R; Ronald Kasoma M; Kalyango JN; Karamagi C; Sekaggya-Wiltshire C
J Clin Tuberc Other Mycobact Dis; 2023 May; 31():100349. PubMed ID: 37181458
[TBL] [Abstract][Full Text] [Related]
19. Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study.
Rahman MT; Hossain F; Banu RS; Islam MS; Alam S; Faisel AJ; Salim H; Cordon O; Suarez P; Hussain H; Roy T
Trop Med Infect Dis; 2023 Dec; 9(1):. PubMed ID: 38276634
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
